Literature DB >> 18305559

Bortezomib therapy in myelofibrosis: a phase II clinical trial.

R A Mesa, S Verstovsek, C Rivera, A Pardanani, K Hussein, T Lasho, W Wu, A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18305559      PMCID： PMC8167436          DOI： 10.1038/leu.2008.32

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

Review 1.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.

Authors:  A Pardanani
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

Review 2.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

3.  Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.

Authors:  A Tefferi; T L Lasho; R A Mesa; A Pardanani; R P Ketterling; C A Hanson
Journal:  Leukemia       Date:  2007-04-26       Impact factor: 11.528

4.  Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.

Authors:  Orianne Wagner-Ballon; Didier F Pisani; Thomas Gastinne; Micheline Tulliez; Ronan Chaligné; Catherine Lacout; Frédéric Auradé; Jean-Luc Villeval; Patrick Gonin; William Vainchenker; Stéphane Giraudier
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

5.  New and old treatment modalities in primary myelofibrosis.

Authors:  Francisco Cervantes; Ruben Mesa; Giovanni Barosi
Journal:  Cancer J       Date:  2007 Nov-Dec       Impact factor: 3.360

Review 6.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

Authors:  Ross L Levine; Animesh Pardanani; Ayalew Tefferi; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716
  6 in total
  7 in total

Review 1.  Therapy of myelofibrosis (excluding JAK2 inhibitors).

Authors:  Alessandro Rambaldi
Journal:  Int J Hematol       Date:  2010-02-24       Impact factor: 2.490

2.  Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.

Authors:  Dongqing Yan; Anthony D Pomicter; Srinivas Tantravahi; Clinton C Mason; Anna V Senina; Jonathan M Ahmann; Qiang Wang; Hein Than; Ami B Patel; William L Heaton; Anna M Eiring; Phillip M Clair; Kevin C Gantz; Hannah M Redwine; Sabina I Swierczek; Brayden J Halverson; Erkan Baloglu; Sharon Shacham; Jamshid S Khorashad; Todd W Kelley; Mohamed E Salama; Rodney R Miles; Kenneth M Boucher; Josef T Prchal; Thomas O'Hare; Michael W Deininger
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

3.  Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

Authors:  Talha Badar; Hagop M Kantarjian; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Jorge E Cortes; Naveen Pemmaraju; Sherry R Pierce; Kate J Newberry; Naval Daver; Srdan Verstovsek
Journal:  Leuk Res       Date:  2015-06-11       Impact factor: 3.156

4.  Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

Authors:  Giovanni Barosi; Elisabetta Gattoni; Paola Guglielmelli; Rita Campanelli; Fabio Facchetti; Simona Fisogni; Judith Goldberg; Roberto Marchioli; Ronald Hoffman; Alessandro M Vannucchi
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

Review 5.  Deactylase inhibition in myeloproliferative neoplasms.

Authors:  Sridurga Mithraprabhu; George Grigoriadis; Tiffany Khong; Andrew Spencer
Journal:  Invest New Drugs       Date:  2010-12-03       Impact factor: 3.850

Review 6.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

7.  Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients.

Authors:  Michelino Di Rosa; Cesarina Giallongo; Alessandra Romano; Daniele Tibullo; Giovanni Li Volti; Giuseppe Musumeci; Ignazio Barbagallo; Rosa Imbesi; Paola Castrogiovanni; Giuseppe A Palumbo
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.